Serial No. 09/781,133

-2-

Group Art Unit: 1654

Listing of Claims

In the claims:

1-23. (Cancelled)

- 24. (Currently Amended) A method for enhancing the bioavailability of a β -amyloid peptide derivative to the brain of a subject, comprising administering to the subject the β -amyloid peptide derivative and a P-glycoprotein inhibitor, wherein said P-glycoprotein inhibitor and said β -amyloid polypoptide derivative are separate chemically distinct compounds and wherein said P-glycoprotein inhibitor is not a β -amyloid peptide derivative, liposome or Tween-80, thereby enhancing the bioavailability of the β -amyloid peptide derivative to the brain of the subject.
- 25. (Previously Presented) The method of claim 24, wherein the β -amyloid peptide derivative is selected from the group consisting of PPI-558, PPI-657, PPI-1019, PPI-578, and PPI-655.
- 26. (Original) The method of claim 25, wherein the β -amyloid peptide derivative is PPI-1019.
- 27. (Original) The method of claim 24, wherein the P-glycoprotein inhibitor is valspodar.
- 28. (Original) The method of claim 24, wherein the P-glycoprotein inhibitor is cyclosporin A.
- 29. (Original) The method of claim 24, wherein the P-glycoprotein inhibitor is selected from the group consisting of antiarrhythmics, antibiotics, antifungals, calcium channel blockers, cancer chemotherapeutics, hormones, antiparasites, local anesthetics, phenothiazines, and tricyclic antidepressants.
- 30. (Original) The method of claim 24, further comprising administering to the subject a cytochrome P450 inhibitor.
- 31. (Original) The method of claim 24, wherein the β -amyloid peptide derivative and the P-glycoprotein inhibitor are administered simultaneously.

6177424214 T-3

Oct-03-03 17:22

Serial No. 09/781,133

-3-

Group Art Unit: 1654

32. (Original) The method of claim 24, wherein the β-amyloid peptide derivative and the P-glycoprotein inhibitor are administered at different times.

33-65. (Cancelled)